Selective Enhancement of REM Sleep in Male Rats through Activation of Melatonin MT1 Receptors Located in the Locus Ceruleus Norepinephrine Neurons

Sleep disorders affect millions of people around the world and have a high comorbidity with psychiatric disorders. While current hypnotics mostly increase non-rapid eye movement sleep (NREMS), drugs acting selectively on enhancing rapid eye movement sleep (REMS) are lacking. This polysomnographic study in male rats showed that the first-in-class selective melatonin MT1 receptor partial agonist UCM871 increases the duration of REMS without affecting that of NREMS. The REMS-promoting effects of UCM871 occurred by inhibiting, in a dose–response manner, the firing activity of the locus ceruleus (LC) norepinephrine (NE) neurons, which express MT1 receptors. The increase of REMS duration and the inhibition of LC-NE neuronal activity by UCM871 were abolished by MT1 pharmacological antagonism and by an adeno-associated viral (AAV) vector, which selectively knocked down MT1 receptors in the LC-NE neurons. In conclusion, MT1 receptor agonism inhibits LC-NE neurons and triggers REMS, thus representing a novel mechanism and target for REMS disorders and/or psychiatric disorders associated with REMS impairments.

[1]  D. De Gregorio,et al.  Melatonin MT1 receptors as a target for the psychopharmacology of bipolar disorder: a translational study. , 2023, Pharmacological research.

[2]  E. V. Van Bockstaele,et al.  The Locus Coeruleus- Norepinephrine System in Stress and Arousal: Unraveling Historical, Current, and Future Perspectives , 2021, Frontiers in Psychiatry.

[3]  W. Gan,et al.  REM sleep promotes experience-dependent dendritic spine elimination in the mouse cortex , 2020, Nature Communications.

[4]  Takeo Watanabe,et al.  Complementary contributions of NREM and REM sleep to visual learning , 2020, Nature Neuroscience.

[5]  M. Kano,et al.  Sparse Activity of Hippocampal Adult-Born Neurons during REM Sleep Is Necessary for Memory Consolidation , 2020, Neuron.

[6]  L. Posa,et al.  Effect of the selective melatonin MT1 receptor partial agonist UCM871 in the activity of noraphineprine neurons of the locus coeruleus during the sleep/wake cycle , 2019 .

[7]  D. De Gregorio,et al.  Melatonin MT1 receptor as a novel target in neuropsychopharmacology: MT1 ligands, pathophysiological and therapeutic implications, and perspectives. , 2019, Pharmacological research.

[8]  P. Pévet,et al.  MT1 and MT2 melatonin receptors are expressed in nonoverlapping neuronal populations , 2019, Journal of pineal research.

[9]  S. Comai,et al.  Sleep well. Untangling the role of melatonin MT1 and MT2 receptors in sleep , 2019, Journal of pineal research.

[10]  S. Comai,et al.  Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep , 2019, Front. Endocrinol..

[11]  P. Sahota,et al.  Melatonin promotes sleep in mice by inhibiting orexin neurons in the perifornical lateral hypothalamus , 2018, Journal of pineal research.

[12]  S. Comai,et al.  Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery , 2018, Pharmacological Reviews.

[13]  P. Fuller,et al.  The Biology of REM Sleep , 2017, Current Biology.

[14]  L. Posa,et al.  S.35.01 Neuropsychopharmacological properties of novel melatonin MT1 receptor ligands , 2017, European Neuropsychopharmacology.

[15]  A. Adamantidis,et al.  REM sleep and memory , 2017, Current Opinion in Neurobiology.

[16]  L. Pinato,et al.  Day/night expression of MT1 and MT2 receptors in hypothalamic nuclei of the primate Sapajus apella , 2017, Journal of Chemical Neuroanatomy.

[17]  M. Dubocovich,et al.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. , 2016, Annual review of pharmacology and toxicology.

[18]  S. Comai,et al.  Antinociceptive properties of selective MT(2) melatonin receptor partial agonists. , 2015, European journal of pharmacology.

[19]  G. Tarzia,et al.  Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways , 2015, Pain.

[20]  S. Comai,et al.  Melancholic-Like Behaviors and Circadian Neurobiological Abnormalities in Melatonin MT1 Receptor Knockout Mice , 2015, The international journal of neuropsychopharmacology.

[21]  F. Rolling,et al.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats , 2015, Gene Therapy.

[22]  Justin R. Dunmyre,et al.  Coupled Flip-Flop Model for REM Sleep Regulation in the Rat , 2014, PloS one.

[23]  G. Tarzia,et al.  Melatonin, selective and non-selective MT1/MT2 receptors agonists: Differential effects on the 24-h vigilance states , 2014, Neuroscience Letters.

[24]  J. Zuber,et al.  An optimized microRNA backbone for effective single-copy RNAi. , 2013, Cell reports.

[25]  G. Hannon,et al.  Creating an miR30-based shRNA vector. , 2013, Cold Spring Harbor protocols.

[26]  S. Comai,et al.  Sleep–wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice , 2013, Behavioural Brain Research.

[27]  M. Mor,et al.  MT1‐Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N‐{[(3‐O‐Substituted)anilino]alkyl}amides , 2012, ChemMedChem.

[28]  R. McLaughlin,et al.  Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood. , 2012, The international journal of neuropsychopharmacology.

[29]  L. Descarries,et al.  Promotion of Non-Rapid Eye Movement Sleep and Activation of Reticular Thalamic Neurons by a Novel MT2 Melatonin Receptor Ligand , 2011, The Journal of Neuroscience.

[30]  Wei Li,et al.  The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity , 2011, The Journal of Neuroscience.

[31]  J. Peever,et al.  Impaired GABA and Glycine Transmission Triggers Cardinal Features of Rapid Eye Movement Sleep Behavior Disorder in Mice , 2011, The Journal of Neuroscience.

[32]  K. Deisseroth,et al.  Tuning arousal with optogenetic modulation of locus coeruleus neurons , 2010, Nature Neuroscience.

[33]  D. Sugden,et al.  Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat , 2009, Neuroscience Letters.

[34]  J. Boutin,et al.  Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. , 2008, Biochemical pharmacology.

[35]  Priyattam J Shiromani,et al.  Effects of Saporin-Induced Lesions of Three Arousal Populations on Daily Levels of Sleep and Wake , 2007, The Journal of Neuroscience.

[36]  Daniel J. Taylor,et al.  Comorbidity of chronic insomnia with medical problems. , 2007, Sleep.

[37]  Joshua J Gooley,et al.  Neurobiology of the Sleep-Wake Cycle: Sleep Architecture, Circadian Regulation, and Regulatory Feedback , 2006, Journal of biological rhythms.

[38]  C. Saper,et al.  A putative flip–flop switch for control of REM sleep , 2006, Nature.

[39]  B. Jones,et al.  From waking to sleeping: neuronal and chemical substrates. , 2005, Trends in pharmacological sciences.

[40]  J. Feldon,et al.  Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats , 2004, Journal of Virology.

[41]  M. Seager,et al.  Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity , 2004, Biological Psychiatry.

[42]  R. Palmiter,et al.  Norepinephrine-deficient mice exhibit normal sleep-wake states but have shorter sleep latency after mild stress and low doses of amphetamine. , 2003, Sleep.

[43]  C. Berridge,et al.  The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes , 2003, Brain Research Reviews.

[44]  Yan Zhu,et al.  A neural circuit for circadian regulation of arousal , 2001, Nature Neuroscience.

[45]  B. Byrne,et al.  Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield , 1999, Gene Therapy.

[46]  R. Thisted,et al.  Sleep and Psychiatric Disorders: A Meta-analysis , 1992 .

[47]  G. Aghajanian,et al.  Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure , 1982, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[48]  F. Bloom,et al.  Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[49]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[50]  Barbara E. Jones,et al.  Effects of locus coeruleus lesions upon cerebral monoamine content, sleep-wakefulness states and the response to amphetamine in the cat , 1977, Brain Research.

[51]  P. Lidbrink,et al.  The effect of lesions of ascending noradrenaline pathways on sleep and waking in the rat. , 1974, Brain research.

[52]  T. Svensson.  Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology , 2004, Psychopharmacology.

[53]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .